Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights November 6, 2025 SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong balance sheet and cash runway into 2028
TITAN Group: Nine-Month 2025 Results November 6, 2025 Regulatory News: Titan SA (Euronext Brussels, ATHEX and Euronext Paris, TITC) announces the nine-month 2025 financial results. Record nine-month EBITDA profitability and a positive outlook Group Sales YTD increased by 1.4%, at €2,013m, thanks to the strong performance in Greece, in the US & in Egypt, driven by increased volumes and overall firm pricing levels. [...]
SES Delivers Solid 9 Months and Q3 2025 Results November 6, 2025 SES S.A. fully consolidates Intelsat from 17 July 2025 and announces financial results for the nine months and three months ended 30 September 2025 with solid operational and financial performance. Solid 9 months 2025 financial performance on a reported basis (Intelsat fully consolidated from 17 July 2025) Revenue of €1,747 million (+19.8% yoy(1)) and Adjusted [...]
IGI Reports Third Quarter and First Nine Months of 2025 Unaudited Financial Results November 4, 2025 International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today reported financial results for the third quarter and first nine months of 2025. Highlights for the third quarter and first nine months of 2025 include: (in millions of U.S. Dollars, except percentages and per share information) Quarter Ended September 30, Nine Months [...]
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months November 4, 2025 Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in TRD, including potential rolling submission Company now plans to disclose 9-week data (Part A) from COMP006 together with 26-week data (Part B) from COMP005 in Q1 2026 Disclosure of 26-week (Part B) COMP006 data expected in early Q3 2026 Cash position of $185.9 million as of September 30, 2025 Conference call on November 4 at 8 am ET (1 pm UK)
Algoma Central Corporation Reports Financial Results for the 2025 Third Quarter November 4, 2025 Milestone 100th vessel, continued fleet growth, new strategic partners, and strong core results define the quarter